Company: RCUS
Filing Date: 2025-04-22
Form Type: DEF 14A
Source: 0001724521-25-000052
Chunk: 56

Company: Arcus Biosciences, Inc.
Filing Date: 2025-04-22
Form: DEF 14A
Chunk 56
---
 option vest in 48 substantially equal monthly installments commencing on August 1, 2022, provided the officer remains in our continuous service through each vesting date.

(5) The shares subject to this RSU award vest in four equal annual installments commencing December 15 of the year of grant, provided the officer remains in our continuous service through each vesting date. Accordingly, the number of shares in the table reflect only those shares subject to the RSU award that remain unvested.

(6) The shares subject to this RSU award vest in four equal annual installments commencing September 15, 2023, provided the officer remains in our continuous service through each vesting date. Accordingly, the number of shares in the table reflect only those shares subject to the RSU award that remain unvested.

<div align='center'>31.</div>

#### 2024 Option Exercises and Stock Vested
There were no exercises of stock options by the named executive officers during the year ended December 31, 2024. The below table describes the number of shares acquired upon vesting of RSUs for the named executive officers during the year ended December 31, 2024.

|                             |     | Stock Awards                         |     |         |     |                              |           |
| Name                        |     | Number of shares acquired on vesting 
 (#)                                  |     |         |     | Value realized on vesting(1) 
 ($)                          |           |
| Terry Rosen, Ph.D.          |     |                                      |     |  99,743 |     |                              | 1,626,117 |
| Robert C. Goeltz, II        |     |                                      |     |  21,000 |     |                              |   337,680 |
| Juan Carlos Jaen, Ph.D.     |     |                                      |     |  47,855 |     |                              |   781,746 |
| Jennifer Jarrett            |     |                                      |     | 129,262 |     |                              | 2,220,033 |
| Dimitry Nuyten, M.D., Ph.D. |     |                                      |     |  26,125 |     |                              |   439,959 |

(1) The amount represents the closing market price of our common stock on the vesting date multiplied by the number of shares of common stock that vested on that date.

#### Severance and Change in Control Benefits
The table below provides